comparemela.com

Latest Breaking News On - Left atrial appendage - Page 4 : comparemela.com

J&J heats up LAA closure competition with $400M Laminar buy

Just days after Medtronic announced it would launch a LAA device, J&J said it has acquired a company that is developing a new treatment for LAA closure.

J&J surprises with $400M Laminar acquisition

Johnson & Johnson completed the previously unheralded acquisition of privately held Laminar Inc. for $400 million upfront, with undisclosed contingent payments depending on achievement of clinical and regulatory milestones starting in 2024. The deal provides the med-tech giant a potentially game-changing entree into the lucrative left atrial appendage (LAA) market.

With Amulet or Watchman, 50% of patients still leak either way

Left atrial appendage (LAA) occlusion procedures are designed to reduce the risk of thromboembolism in patients who have non-valvular atrial fibrillation, but a study presented at the 2023 Transcatheter Cardiovascular Therapeutics annual meeting in San Francisco demonstrated that about half of patients continue to have LAA leaks – and potentially the risk of dangerous blood clots and stroke – a year after the procedure.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.